 
 
 
 
 
 
 
 
 
#1740  Lipoic Acid for Treatment of Progressive Multiple Sclerosis  
Funding Agencies : Rehabilitation Research & Development , National Multiple Sclerosis 
Society , MS Society of Canada  
Principal Investigator /Study Chair : Rebecca Spain  
Version 8.0: 18 February  2021 
Approved 30 March 2021  
NCT# 03161028  
 
 
 
 
 
 
 
 VA Central IRB Protocol Template – version 10/26/2012  Page 2 of 48 
  
 
INVESTIGATOR AGREEMENT  
 
Protocol Version 8.0 
Lipoic Acid for Treatment of Progressive Multiple Sclerosis  
 
By signing, the Investigator agrees to  have read the foregoing protocol and agree s to 
conduct the study as described herein.  
 
The Investigator agrees to k eep all study documents  stored appropriately to ensure their 
confidentiality. The Investigator should not disclose study  information to others without 
authorization, except to the extent necessary to conduct the study.  
 
 
 
 
 
_____ ________________________________  
Investigator Name (Print)  
 
 
______________________________________  _______________________  
Investigator Signature      Date  
 
 
 
 
 VA Central IRB Protocol Template – version 10/26/2012  Page 3 of 48 
  
 
Synopsis  
Study Investigator/Sponsor:  Rebecca Spain, MD, MSPH  
Funding Sources:  VA Merit re view (RX002682 -01, RR&D) National MS Society  (R-
1705 -27628) , MS Society of Canada  
Investigational product:  Lipoic acid (previous names alpha lipoic acid, thiotic acid). 
Investigational drug provided by Pure Encapsulations®  
IND#: 110132  
Title: Lipoic acid f or treatment of progressive multiple sclerosis.  
Study Centers: VA and non -VA MS Centers (United States), Ottawa, Ontario (Canada)  
Study Sites : VA Portland Health Care System  (VAPORHC S), VA Puget Sound Health 
Care System, Washington DC VA Medical Center , VA Salt Lake City Health Care 
System , Dallas VA Medical Center, Ottawa Hospital Research Institute, Swedish 
Medical Center, University of Alabama at Birmingham, University of Utah, University of 
Vermont , and University of Colorado . 
Duration of Study:  Approxi mately 2 years  Phase of Development: Phase 2  
Study Objectives:  
Primary objective:  
• Determine if lipoic acid (LA) is superior to placebo at 2 years in maintaining a 
clinically meaningful outcome, mobility, as measured by the primary outcome of 
change in comp letion time of the Timed 25 Foot Walk (T25FW). Two Minute 
Timed Walk (2MTW) and fall count will be evaluated to confirm the primary 
outcome results.  
 Secondary objectives:  
• Determine if LA is superior to placebo at 2 years in slowing whole brain atrophy 
with an estimated 40 -50%% effect size. Additional secondary outcome measures 
will include neurological disability, cognition, mood, and quality of life.  
• Monitor safety and tolerability of LA via laboratory testing and adverse event 
reporting.  
Study Design:  Participants with primary progressive and secondary progressive 
multiple sclerosis ( MS) will be randomized on a 1:1 basis to LA or placebo. Subjects will 
 VA Central IRB Protocol Template – version 10/26/2012  Page 4 of 48 
 complete 7 study visits over 2 years. Walking tests and secondary outcome measures 
will be performed at  every visit. MRIs will be completed at baseline and study end. 
Safety lab oratory measure s will be  collected at every study visit . The sample size of 59 
per arm will allow for a 25% drop -out rate.  
List of Abbreviations  
ACR, albumin to creatinine ratio  
AE, Adverse Event  
AIRC, Advanced Imaging Research Center  
ALP, alkaline phosphatase  
ALT, alanine aminotransferase  
AST, aspartate aminotransferase  
BBB, blood brain barrier   
BDP, Biostatistics & Design Program  
BND, Biorepository for Neurological Diseases  
CCC, Cli nical Coordinating Center  
CDA, Career Development Award  
CFR, Code of Federal Regulations  
CNS, central nervous system  
DCC, Data Coordinating Center  
DMT, disease -modifying therapies  
DSMB, Data Safety and Monitoring Board  
EAE, experimental autoimmune encephal omyelitis  
EDSS, Expanded Disability Status Scale  
eGFR, estimated glomerular filtration rate  using MDRD calculation  
FESI, Falls Efficacy Scale -International  
FDA, Food & Drug Administration  
GGT, gamma -glutamyl transferase  
GI, gastrointestinal  
GLTEQ, Godin Le isure -Time Exercise Questionnaire , modified  
ICF, informed consent form  
IND, Investigational New Drug  
IRB, Institutional Review Board  
LA, lipoic acid  
LSI, local site investigator  
M, month  
MDRD, Modification of Diet in Renal Disease  
MedDRA, Medical Dictiona ry for Regulatory Activities  
MPRAGE, Magnetization Prepared Rapid Acquisition Gradient Echo  
MS, multiple sclerosis  
 VA Central IRB Protocol Template – version 10/26/2012  Page 5 of 48 
 NMSS, National Multiple Sclerosis Society  
OCTRI, Oregon Clinical & Translational Research Institute  
OHSU, Oregon Health & Science University  
PCBV, percent change brain volume  
PCP, Primary Care Provider  
PD, Protocol Deviation  
PHI, protected health information  
PMS, progressive multiple sclerosis  
QC, quality control  
RCT, randomized controlled trial  
RIC, Recruitment Innovation Center  
RRMS, relapsi ng-remitting multiple sclerosis  
SAE, serious adverse events  
SBQ -R, Suicide Behaviors Questionnaire -Revised  
SC, Subcutaneous   
SCC, Statistical Coordinating Center  
SDMT, Symbol Digit Modalities Test  
SIENA, Structural Image Evaluation using Normalization of A trophy  
SPMS, secondary progressive multiple sclerosis  
T, Tesla  
T25FW, Timed 25 Foot Walk  
UP, Unanticipated Problem  
 VA Central IRB Protocol Template – version 10/26/2012  Page 6 of 48 
  Table of Contents  
 
Synopsis  ................................ ................................ ................................ ...............................  3 
List of Abbreviations  ................................ ................................ ................................ ..........  4 
Table of Contents  ................................ ................................ ................................ ................  6 
Protocol Title  ................................ ................................ ................................ ........................  9 
1.0 Key Study Personnel/Study Centers  ................................ ................................ ...... 9 
2.0 Intr oduction  ................................ ................................ ................................ ..............  10 
3.0 Objectives  ................................ ................................ ................................ .................  12 
4.0 Resources and Personnel  ................................ ................................ ......................  13 
5.0 Study Procedures  ................................ ................................ ................................ .... 15 
5.1 Study Design  ................................ ................................ ................................ ....... 15 
5.1a Design and specific aims  ................................ ................................ ...........  15 
5.1b Study population  ................................ ................................ ........................  15 
5.1c Study timeline and visit scheduling  ................................ ...........................  15 
5.1d Unscheduled visits for relapse evaluation an d adverse events  ..............  16 
5.1e Source of investigational drug  ................................ ................................ ... 17 
5.1f Investigational new drug  ................................ ................................ .............  18 
5.1g Labeling  ................................ ................................ ................................ ...... 18 
5.1h Blinding  ................................ ................................ ................................ ....... 18 
5.1i Duration of treatment  ................................ ................................ ..................  18 
5.1j Randomization ................................ ................................ .............................  18 
5.1k Compliance and medication reconciliation  ................................ ...............  18 
5.1l Risks ................................ ................................ ................................ .............  18 
5.1m Protection  from risks  ................................ ................................ .................  19 
5.1n Data banking  ................................ ................................ ..............................  22 
5.1o. Optional biorepository participation ……………………………………… .22 
5.2 Recruitment Methods  ................................ ................................ ..........................  23 
5.2a Recruitment goal  ................................ ................................ ........................  23 
5.2b Subject identification/recruitment  ................................ ..............................  23 
5.2c Recruitment of specific subpopulations  ................................ ....................  24 
5.2d Recruitment of Veterans  ................................ ................................ ............  24 
5.2e Sources of materials  ................................ ................................ ..................  24 
5.2f Benefits  ................................ ................................ ................................ ........  24 
5.2g Cost to subjects ................................ ................................ ..........................  24 
5.2h Subject compensation  ................................ ................................ ...............  25 
5.3 Informed Consent Procedures  ................................ ................................ ...........  25 
5.4 Inclusion/Exclusion Criteria  ................................ ................................ ................  25 
5.5 Study Evaluations  ................................ ................................ ...............................  27 
5.5a Study flowsheet  ................................ ................................ ..........................  27 
 VA Central IRB Protocol Template – version 10/26/2012  Page 7 of 48 
 5.5b Consent, medical  history, general medical exam  ................................ .... 29 
5.5c Vital signs  ................................ ................................ ................................ ... 29 
5.5d Concomitant medication review  ................................ ................................  29 
5.5e Safety laboratory analyses  ................................ ................................ ........  29 
5.5f Inclusion/Exclusion review  ................................ ................................ .........  29 
5.5g Walking tests  ................................ ................................ ..............................  30 
5.5h EDSS  ................................ ................................ ................................ ..........  30 
5.5i 9HPT  ................................ ................................ ................................ ............  30 
5.5j Cognitive tests  ................................ ................................ .............................  30 
5.5k Patient -reported outcome measures  ................................ ........................  31 
5.5l Fall count  ................................ ................................ ................................ ..... 31 
5.5m MRI procedures ................................ ................................ .........................  31 
5.5n Suicidality monitoring  ................................ ................................ .................  32 
5.5o Adverse event monitoring  ................................ ................................ ..........  32 
5.5p Investigational drug dispensing ................................ ................................ . 33 
5.5q Subject/provider blinding questionnaire  ................................ ...................  33 
5.5r Subject disposition form  ................................ ................................ .............  33 
5.6 Data Analysis ................................ ................................ ................................ ....... 33 
5.6a Sample size  ................................ ................................ ................................  33 
5.6b Data analysis plan ................................ ................................ ......................  33 
5.7 Withdrawal of Subjects  ................................ ................................ .......................  35 
6.0 Reporting  ................................ ................................ ................................ ..................  35 
6.1 Adverse event reporting ................................ ................................ ......................  36 
6.2 Limited collection of non -serious AE  ................................ ................................ .. 36 
6.3 Limited reporting of AE  ................................ ................................ .......................  36 
6.3a Limited reporting of AE, UP, and PD to the DCC  ................................ .... 36 
6.4 Adverse event definition  ................................ ................................ .....................  37 
6.5 Serious adverse event definition  ................................ ................................ ........  37 
6.6 Unanticipated problem definition  ................................ ................................ ........  37 
6.7 Protocol deviation  ................................ ................................ ................................  37 
6.7a Mild PD  ................................ ................................ ................................ ....... 37 
6.7b Moderate PD  ................................ ................................ ..............................  38 
6.7c Severe PD  ................................ ................................ ................................ .. 38 
6.8 Data and Safety Monitoring Plan  ................................ ................................ ....... 39 
7.0 Privacy an d Confidentiality  ................................ ................................ ....................  39 
7.1 Protected health information  ................................ ................................ ..............  39 
7.2 Privacy and confidentiality  ................................ ................................ ..................  40 
7.3 Information and specimen management  ................................ ...........................  40 
8.0 Communication Plan ................................ ................................ ...............................  42 
8.1 Multi -site study coordination plan  ................................ ................................ ....... 42 
 VA Central IRB Protocol Template – version 10/26/2012  Page 8 of 48 
 8.2 Ongoing communication  ................................ ................................ .....................  42 
8.3 Study monitoring  ................................ ................................ ................................ . 43 
9.0 References ……………………………………………………………………………. .44 
 VA Central IRB Protocol Template – version 10/26/2012  Page 9 of 48 
 Protocol Title:   Lipoic Acid for Treatment of Progressive Multiple Sclerosis  
1.0 Key Study Personnel /Study Centers  
A current personnel list is provided with the manual of operations  
Principal Investigator /Study Chair : 
Rebecca Spain, MD, MSPH  
VA Portland Health Care System  
L226, 3181 SW Sam Jackson Park Road  
Portland, OR, 97239  
Ph: (503) 346 -0768  
Fax: (503) 346 -6921  
spainr@ohsu.edu  (preferred); Rebecca.Spain @va.gov  
Project Ma nager:  
Carin Waslo, MPH  
VA Portland Health Care System  
waslo@ohsu.edu  (preferred) ; Carin.Waslo@va.gov  
Clinical Coordinating Center (Rebecca Spain)  
VA Portland Health Care System  
 
Data Coordinating Center  
Oregon Clinica l & Translational Research Institute  (OCTRI)  
Oregon Health & Sciences University (OHSU)  
Portland, OR  
 
Statistical Coordinating Center  
OHSU Biostatistics & Design Program (BDP)  
Portland, OR   
 
Central MRI Reading Site  
OHSU Advanced Imaging Research Center  
Portland, OR   
 
 
 VA Central IRB Protocol Template – version 10/26/2012  Page 10 of 48 
 2.0 Introductio n 
Scientific Rationale and Significance  
Multiple sclerosis (MS) is a chronic progressive autoimmune disease of the central 
nervous system (CNS), and the most common neurologic disease of young adults 
including Veterans. More  than 2.5 million people worldwide and around 500,000 people 
in the U.S live with MS. At any time, nearly half have a progressive MS (PMS) 
phenotype characterized by clinical worsening in the absence of exacerbations 
associated with CNS inflammation (1). Mobility deficits are a hallmark of MS with 
approximately half of all patients requiring a walking aid by 15 years after diagnosis . MS 
is divided into subtypes according to its course. About 85% people present with a 
relapsing -remitting MS (RRMS) subtype, then transition into a s econdary progressive 
subtype (SPMS) after 10 -20 years. The remaining 10 -15% present with unremitting 
progression from onset called primary progressive MS (PPMS) (2). Taken together , 
PPMS and SPMS are termed progressive MS (PMS). Patients with PM S, including 
veterans, use a disproportionate quantity of social and medical services, and report a 
lower quality of life than RRMS (3). 
MS is traditi onally considered an inflammatory disorder characterized by episo dic CNS 
demyelination but current understanding is that neurodegeneration accompanies 
progression from disease onset. Neurodegeneration causes generalized atrophy 
throughout the CNS including  the brain, spinal cord, and optic nerves (4-6). Atrophy of 
both the brain and spinal cord can be observed on MRI using now standard post -
processing techniques (7). Targeting specific mechanisms of neurodegeneration is a 
rational strategy for development and validation of therapeutic interventions for PMS.  
Lipoic acid (LA) is an endogenously -produced eight carbon sulfur -containing fatty acid 
that is synthes ized de novo in plants and animals. Endogenous LA is bound to pro teins 
and is involved in acyl transfer reactions (8). It can also be absorbed from natural food 
sources and nutritional supplements. LA and its reduced form dihydrolipoic acid (DHLA) 
form a redox couple serves as a cofac tor for at least five enzymes. LA in addition has 
antioxidant fun ctions including free -radical scavenging, metallic ion chelation, 
regeneration of intracellular glutathione, and repair of oxidative damage to 
macromolecules (9). In mitochondria, the LA/DHLA redox couple serves as a key co -
factor for the pyruvate dehydrogenase complex of oxidative respiration, and aids 
synthesis of nucleic acid s (10). LA is involved in modulation of signal transduction 
including the PKB/Akt signaling pathway important for vascular endothelial integrity, 
redox -sensitiv e transcription factors including Nrf2, and acts as an insulin mi metic to 
reduce insulin resistance (11, 12) . LA is available as an inexpensive dietary 
 VA Central IRB Protocol Template – version 10/26/2012  Page 11 of 48 
 
 supplement, and the most common synthetic formulation of LA is the racemic mixture of 
its R and S enantiomers.  
Our center and o thers have shown that LA reduces impairment in a dose -dependent 
fashion in the murine model of MS, experimental autoimmune encephalomyelitis (EAE) 
(13, 14). Our center has also shown that LA is safe and tolerated in people with MS, 
and conducted dose -finding pharmacokinetic (PK) studies. O ral administration of LA at 
1200 mg/day produces easily detectable blood levels in people with MS and achieves 
level s comparable to therapeutic blood levels in mice with EAE (15). The same dose of 
LA has been used in trials for diabetic polyneuropathy and shown to be well -tolerated in 
two year trials for this indication (16). The most common adverse reactions in LA trials 
are gastrointestinal intolerance, headache, malodourous urine, and rash (16, 17) . One 
participant in our Center’s prior clinical t rial of LA in secondary progressive MS and one 
in the currently ongoing study developed biopsy -proven membranous 
glomerulonephritis  (18). Both participants developed urine protein and limb edema 
leading to the diagnosis. At 6 months follow -up from study ex it, the participant no longer 
had abnormal labs, edema, or required nephrologist care. This participant is under 
ongoing care monitoring.  
We discovered that LA significantly reduced brain atrophy in people with SPMS 
compared to placebo in our  pilot random ized controlled trial ( RCT, see Preliminary 
studies) (18). The natural antioxidant, LA, produced a significant reduction in brain 
atrophy assessed by MRI in people with secondary progressive MS (SPMS).  
Additionally, the LA cohort had a trend toward improvement in walkin g tests and a 
reduction in falls. Importantly, LA was safe, well tolerated, and had very high 
compliance.  
Significance : The impressive results of the pilot LA in SPMS trial make LA an attractive, 
safe, natural, and tolerated DMT candidate for people who suffer from PMS. The goal of 
this larger, multi -site, Phase  2 RCT of LA in a broader PMS population is to confirm the 
effects on brain atrophy rate reduction and 
to establish the clinical benefits of LA.  
Preliminary Studies  
LA suppresses EAE, the animal m odel of 
MS, in a dose -dependent fashion. In a 
study of EAE mice treated with LA before 
disease onset, LA in doses of 100 
mg/kg/day, 50 mg/kg/day, and 20 
mg/kg/day were all effective in Fig. 1. Dose -response curve of EAE 
suppression in LA -treated mice.  
 VA Central IRB Protocol Template – version 10/26/2012  Page 12 of 48 
 
Figure 4. LA reduces brain atrophy in 
SPMS partic ipants using intention -to-
treat analysis.  suppressing EAE (19). An LA dose of 20 mg/kg/day suppressed EAE development by 
almost 50%  (according to Cumulative Disease Scores scores), a dose of 50 mg/kg/day 
suppressed EAE by ~80%, and a dose of 100 mg/kg/day suppressed EAE by 100% 
over 10 days (Fig.1).  
PK studies in EAE and humans have determined the human equivalent dose to the 
therape utically effective dose in EAE. Two PK studies of LA in people with MS were 
conducted at OHSU and determined that doses of 1200mg taken with food were easily 
detectable LA  levels in the serum and had reasonable gastrointestinal tolerability (15, 
17). A formulation from the PK studies was used in the pilot LA in SPMS trial and will be 
used again in the current trial of LA in PMS.  
Spain et al conducted a single -center, 2 -year 
randomized, double -blind, placebo -controll ed 
phase 2 trial (n=51) of daily oral LA in SPMS 
(18). The LA cohort demonstrated a 68% 
reduction in the annualized rate of whole 
brain atrophy (0.21% vs -0.65%, p = 0.002, 
Fig 4). Although not powered to detect 
clinical outcomes, the LA cohort had a trend 
toward improv emen t in walking speed in the 
T25FW ( -0.54 SD 0.36 vs 0.14 SD 0.25, p = 
0.06). Overall LA was safe and well tolerated 
with high compliance and  at the time,  no 
unexpected deleterious adverse events (AE) 
were attributed to LA.  A later review of AE’s 
in light of safety data emerging from the 
present study indicate that the serious 
adverse event of biopsy -proven glomeru lonephritis  and a second case of proteinuria  in  
subject s in the LA cohort was  related to lipoic acid (see above).  To date, all three cases 
resolved  within a 3-12 month period.  Gastrointestinal (GI) upset was significantly 
greater in the LA cohort compared to placebo (17% v 3% p = 0.004). Unexpectedly, the 
LA cohort had a significantly lower number of falls than the placebo cohort (15% v 38%, 
p = 0.03 ). The results of this study formed the basis of the current research trial.  
3.0 Objectives  
Hypothesis:   The purpose of this study is  to determine if the oral antioxidant LA provides 
clinical benefits and reduces brain atrophy in PMS. The hypothesis is  that d aily LA will 
both maintain mobility and reduce whole brain atrophy, thus pavin g the way for 
 VA Central IRB Protocol Template – version 10/26/2012  Page 13 of 48 
 consideration of LA as a disease -modifying therapy for PMS.  The specific aims of this  
multi -center RCT of 1200mg oral daily LA versus placebo in PMS are: 
Specific A im 1. Determine if LA is superior to placebo in maintaining mobility as 
measured by the primary outcome  of change in completion time of the Timed 25 Foot 
Walk (T25FW). Secondary outcomes are changes in the 2 Minute Timed Walk (2MTW) 
and fall count for cons istency of the effects of LA on mobility.  
 
Specific Aim 2. Determine if LA is superior to placebo in slowing whole brain atrophy 
with an estimated 40 -50%% effect size. Additional secondary outcome measures are 
changes in neurological disability, cognition , mood, and quality of life.  
 
Specific Aim 3. Monitor safety and tolerability via laboratory testing and adverse event 
reporting.  
4.0 Resources and Personnel  
The research study will be conducted at both VA and non -VA study sites.  VA Portland 
Health Care Syst em (VAPORHCS ) is the lead study site  and serves as the Clinical 
Coordinating Center (CCC) . The Oregon Clinical & Translational Research Institute 
(OCTRI) within Oregon Health & Science University (OHSU, Portland, OR) will serve as 
the Data Coordinating Cen ter (DCC). The Statistical Coordinating Center (SCC) is 
housed in the  OHSU  Biostatistics & Design Program (BDP) . The OHSU Advanced 
Imaging Research Center will act as the Central MRI Reading Site . 
Rebecca Spain is the Grant  PI and the Sponsor -Investigator for this IND study. Dr. 
Spain is  responsible for the overall conduct of the study. She has access to PHI from all 
study subjects.  She is permitted to be  the LSI and treating neurologist  at VAPORHCS . 
Local Site  Investigators  (LSI) : Each study site has a LSI that is responsible for the 
overall conduct of the study at their site  including regulatory oversight . The LSI has 
access to PHI for subjects from their site only.  
Site treating neurologist: The treating neurologist is responsible for reviewing the 
inclu sion/exclusion criteria, conducting  the screening medical history and exam, 
reviewing safety laboratory results, adverse event recording and reporting, and 
conducting unscheduled visits as needed for adverse event evaluation. The site treating 
neurologist has access to PHI for subjects from their site only. The treating neu rologist 
may also hold the role of  LSI. 
 VA Central IRB Protocol Template – version 10/26/2012  Page 14 of 48 
 Project Manager (PM): This person at principal study site (Portland) will assist the study PI 
in all aspects of study management and coordination. The PM will not collect  primary data 
from subjects. The PM will work closely with all study team members to attain initial IRB 
approval, ensure the accurate and timely collection and recording of study data, monitor 
recruitment, assist with site IRB submis sions and revisions, improve study logistics, 
conduct conference calls, tabulate data for the DSMB, and assist in any other aspects of 
study required for successful completion. The PM will serve as the study monitor. The PM 
has access to PHI for all study subjects.  
Site blinded EDSS examiners: EDSS examiners must have training in the neurological 
exam and experience conducting EDSS exams. The blinded EDSS examiner should not 
be the usual treating neurologist of the subject in order to maintain the blind. The blinded 
EDSS examiners may have access to PHI for subjects from their site only.  
Central Research Pharmacy: Portland VA Research Pharmacy will act as the Central 
Research Pharmacy  for the entire study . They will receive bulk study drug from the 
product d onor and redistribute it to US study site Research Pharmacies who then  prepare 
study drug for individual subjects. The Central Research Pharmacy works with the SCC  to 
maintain the randomization lists for each study site.  The Central Research Pharmacy has 
access to PHI for all study subjects.  
Site research pharmacies : The US site research pharmacies will receive study drug from 
the Central Research Pharmacy and package it for individual subjects according to the 
randomization schedule. They will also provid e medication reconciliation reports.  The 
Canadian site research pharmacy will receive study drug directly from the product donor 
and then perform the same functions as the US site pharmacies. The site research 
pharmacies have access to PHI for subjects fro m their site only.  
Clinical Coordinating Center (CCC): VAPORHCS will serve as the CCC. The CCC will 
serve as the primary communication hub between study sites, study centers, and 
monitoring bodies.  
Data Coordinating Center (DCC): The DCC and the PM will w ork closely to set up and 
maintain the study database, create policies and procedures for the study, monitor data 
quality and accuracy, and help create DSMB reports.  The DCC will receive reports from all 
study sites regarding adverse events (AE), serious a dverse events (SAE), unexpected 
problems (UP), and protocol deviations (PD) and ensure proper reporting to IRBs per 
reporting requirements.  
 VA Central IRB Protocol Template – version 10/26/2012  Page 15 of 48 
 Statistical Coordinating Center (SCC): The SCC will conduct all data analyses, assist in 
DSMB reports, and create al l final reports, figures, and statistical analysis sections of 
manuscripts that result from this study. The SCC will have access to PHI from all subjects.  
Central MRI Reading Site:  The Central MRI Reading Site  will receive MRI images from all 
study sites,  perform QC monitoring of images and facilities, provide feedback on image 
quality issues, conduct all study relate d image analyses, and enter the analysis results into 
the study  database.  The Central MRI Reading Site will have access to PHI from all study  
subjects.  
Data Safety and Monitoring Board (DSMB): The DSMB will develop the DSMB charter and 
will meet at least yearly to review aggregate safety data and study progress. The DSMB  
will provide a report to the PI with recommendations regarding ongoing con duct of the 
study.  As a member of the DSMB, Dr. Mary Samuels will be the Medical Monitor for this 
study. Dr. Rupali Avasare, a nephrologist at OHSU, will monitor any abnormal kidney 
function at the time of entry of during the course of treatment. The DSMB will have access 
to PHI from all study subjects.  
5.0 Study Procedures  
5.1 Study Design  
5.1a.  Design and specific aims:  This is a phase 2 , double -blind, multi -center RCT  to 
compare the daily administration of 1200 mg oral LA to a placebo, as a disease -
modifying  treatment in PMS. A total of 118 subjects with PMS will be randomized 1:1 to 
LA or placebo. None of the study procedures involve usual care. All study procedures 
will be covered by study funding.  
5.1b.  Study population : A convenience sample of adults with  PMS will be recruited 
from the study sites. The multi -site design of the trial is intended to promote 
generalizability of the study results.  
5.1c.  Study timeline and visit scheduling.  The anticipated study recruitment period is for 
the first 18 months on ce the study is approved at the first study site or until enrolment is 
completed, whichever occurs first.  The study will end when the last participant exits the 
study. There should be no more than 60 days inclusive between the screen and 
baseline visits. S ubsequent study visits will occur at 3 months, 6 months, and every 6 
months thereafter, each visit within +/ - 2 weeks from the ideal visit based on the 
baseline/ month zero (M0) visit. The MRI can take place up to 2 weeks prior to the 
baseline and final vis its. Should the final MRI be postponed for any reason until after the 
 VA Central IRB Protocol Template – version 10/26/2012  Page 16 of 48 
 final visit, the subjects should continue taking study drug until the MRI has been done. 
Reasons for conducting visits outside the scheduling window are recorded.  
 
Performance on clinica l measures may be subject to variation due to the day -to-day 
fluctuations characteristic of PMS. Effects of fluctuations on study outcomes will be 
minimized by encouraging subjects to maintain their usual sleep, eating, and medication 
intake patterns on st udy days. Study visits will be scheduled at the same time -period 
each visit (morning versus afternoon). Study visits may be postponed for concurrent 
non-MS related illness affecting neurological performance on the discretion of the 
treating neurologist.  
 
5.1d. Unscheduled visits for relapse evaluation and adverse events (AE):  Unscheduled 
visits will occur in the event of MS clinical relapses or investigations of AE of at least 
moderate severity considered directly related to the study drug or study procedur es. 
The unscheduled visit for AE is for the purpose of evaluation by the treating neurologist, 
documentation, and reporting according to IRB guidelines. If sufficient medical 
documentation by other health providers for the symptoms of the AE exist, or if t he 
symptoms had resolved by the time of reporting, the treating neurologist may use the 
medical documentation or telephone interview in lieu of an unscheduled visit. 
Asymptomatic elevations or depression in laboratory values considered related to the 
inves tigational drug do not require an unscheduled visit but instead follow the 
monitoring procedure (5.1m. Protection from risks).  If AEs warranting an unscheduled 
visit are noted during a scheduled study visit, procedures for both the unscheduled visit 
for A E and the scheduled study visit are completed. An unscheduled visit for AE 
evaluation includes  collection of case report forms for :  
 AE evaluation documentation including event history  
 General m edical exam  
 Vital signs  
 Concomitant medications  
 Safety la boratory measures (per treating neurologist discretion)  
 Adverse events monitoring  
 SBQ -R 
A protocol -defined MS clinical relapse is defined as new or recurrent neurological 
symptoms, not associated with fever or infection, lasting for at least 24 hours, w hich is 
 VA Central IRB Protocol Template – version 10/26/2012  Page 17 of 48 
 followed by a period of stability or improvement. In addition, a protocol -defined relapse 
requires an increase in the EDSS Functional System corresponding  to the symptom(s) 
of the relapse, or an increase in the overall EDSS secondary to a functiona l change 
related to symptoms(s) of the relapse. A relapse is not considered an adverse event. 
MS c linical relapses can occur in PMS and may be treated by the usual treating 
neurologist with standard courses of intravenous methylprednisolone or oral steroid s of 
less than 2 weeks duration.  
An unscheduled visit should be conducted within 1 week of a reported MS clinical 
relapse. The unscheduled visit for MS clinical relapse evaluation includes:  
 MS clinical relapse evaluation documentation including  
 General medical exam  
 Vital signs  
 Concomitant medications  
 EDSS examination (blinded)  
 Safety laboratory measures (per treating neurologist discretion)   
 Adverse events monitoring  
 SBQ -R 
Subjects who have discontinued the investigational drug for adverse events including 
laboratory monitoring (see section 5.1m.) do not require unscheduled visits for 
subsequent MS clinical relapses.  
Scheduled study visits involving MRIs will be delayed for at least 3 0 days following  high 
dose oral or intravenous  corticosteroid tr eatment  given for any indication .  MS clinical 
relapses not treated with corticosteroids do not affect study visit scheduling. Ongoing 
MS clinical relapses noted during a scheduled study visit have procedures for both the 
unscheduled visit for MS clinical relapse and the scheduled study visit completed.  
Subjects who withdraw early from the study follow the procedures outlined in 
Withdrawal of Subjects (sec 5.7).  
 5.1e.  Source of investigational drug.  Pure Encapsulations®, which follows Good 
Manufacturing Pr ocedures in their production of LA, will provide gelatin capsules 
 VA Central IRB Protocol Template – version 10/26/2012  Page 18 of 48 
 containing 600 mg of LA and the encapsulated placebo rendered to appear similar to LA 
(Letter of support, Appendix A).  
5.1f.  Investigational New Drug (IND).  Dr. Spain holds an IND for test ing LA in PMS 
(#110132). The current proposed study has been  added as an amendment to the 
current IND. Reporting requirements to the FDA will be followed.  
5.1g.  Labeling:  The investigational product will have a label that will be visible on the 
pertinent s torage containers. The label or labeling of an investigational new drug shall 
not bear any statement that is false or misleading in any particular and shall not 
represent that the investigational new drug is safe or effective for the purposes for which 
it is being investigated.   
5.1h.   Blinding . Blinding of the investigational drug will be implemented by the site 
research pharmacies using identical containers, and instructions. The Central Research 
Pharmacy will maintain a master record of subject assignmen t. Subjects and all 
personnel involved in conducting the trial will remain blinded to treatment assignment 
and undergo a blinding questionnaire at study end.  
 
5.1i.  Duration of treatment:  Treatment with study drug will be for 2 years. Treatment 
will exten d beyond 2 years if the final study visit is postponed. See section 5.7 for 
reasons for early termination of treatment.  
 
5.1j.  Randomization . The assignment of subjects to the treatment arms will be based 
on permuted block randomization defined by study s ite. The Central  Research 
Pharmacy and SCC will oversee the randomization schedule. The Central Research 
Pharmacy will also maintain a master list of all study subjects in order to ship 
appropriate amounts of bulk study drug to the  US site pharmacies for i ndividual subject 
packaging and shipping.  
5.1k.   Compliance  and medication reconciliation : Compliance with taking the 
investigational drug will be encouraged at each visit and between visits by telephone 
calls. Unused pills will be collected at each study  visit and if necessary, by mail between 
visits. The study site research pharmacies will conduct medication reconciliation with 
returned pills and provide feedback to research staff  to monitor  if compliance is less 
than 75% or more than 125% of prescribed doses to encourage proper compliance.  
5.1l. Risks:  Risks of the investigational drug, study procedures, and potential loss of 
confidentiality are reviewed with potential subjects during the informed consent process. 
Risks, reporting, responses to risks, an d methods to minimize risks are further outlined 
in section 6.0, Reporting and 7.0, Privacy and Confidentiality. Briefly, risks of the 
 VA Central IRB Protocol Template – version 10/26/2012  Page 19 of 48 
 investigational drug are minimized by adverse event reporting safety and safety 
laboratory studies. Risks of study proced ures are minimized by careful screening 
proced ures and trained study personnel. Risks of loss of confidentiality are minimized 
by limiting collection of PHI, limiting access of PHI to the minimum necessary study 
staff, and use of secure data transfer metho ds. 
Risks of LA: Oral LA can cause physical side effects including gastrointestinal (GI) 
intolerance, nausea and vomiting and rash. LA may cause liver, renal and urinary 
disorders. There is a possibility of developing proteinuria and/or membranous 
glomerul onephritis due to study drug.  It is not known how LA could affect a fetus. LA 
may increase the risk of hypoglycemia in diabetics. The risks of LA taken with DMTs or 
with alcohol are unknown.  
Risks of study procedures and loss of confidentiality: There is a risk of falls and injury 
during gait testing. The MRI magnet can cause metal in the body to move, heat, and 
cause injury. The MRI space is small, so those with claustrophobia are at risk of 
discomfort during the study. There is a risk of psychological ha rm from incidental 
findings unrelated to the study found on MRI such as brain tumors, stroke, other. The 
risks of blood draws include discomfort, vasovagal syncope, bleeding, bruising, and 
infection. The risks of clinical testing and patient -reported outco me measures include 
psychological discomfort from discovering or reporting deficits due to MS. There is a risk 
of loss of confidentiality of the study data.  
5.1m.  Protection from risks:  The informed consent process will inform potential subjects 
of the ris ks of participation. The study will be conducted with IRB  oversight. Procedures 
in this study were specifically designed to minimize risks to the subjects. The 
investigators will adhere to the Data and Safety Monitoring Plan  (sec. 6.2) . Trained 
study perso nnel will perform all data collection, and information will be coded with a 
subject identifier to protect subject confidentiality. Findings that could affect the subjects’ 
health or welfare will be reported to the appropriate authorities (e.g. IRB) and 
communicated to the subjects and appropriate medical service (s) which could include 
the primary care physician.  
Risks to subjects from LA will be minimized by excluding unsuitable patients from 
enrollment, reviewing medical histories and medications at each s tudy visit for potential 
interactions with the investigational drug, reviewing AEs for relation to investigational 
drug, and requiring unscheduled visits for AE evaluation and management.  
To minimize the possible GI side effects of oral LA, we recommend s ubjects take the 
investigational drug with food, or if necessary, to divide the daily dose, or the dose 
 VA Central IRB Protocol Template – version 10/26/2012  Page 20 of 48 
 reduced by 50% at the discretion of the treating neurologist.  Serum renal panels and 
urinalyses will  monitor for kidney damage at every visit.  
Trained phlebotomists will perform blood draws to minimize the associated risks of 
blood draws. Safety  monitoring laboratory panels will monitor for liver, kidney, and 
hematological problems, pregnancy for women of childbearing potential and changes in 
HbA1c.   
a. Proteinuria monitoring : Subjects  must have urine protein monitored every 3 
months  for the duration of the study.  Subjects  must pause  study drug if they 
skip or miss a visit until draw can occur.   
Subjects with baseline (screening) negative or trace proteinu ria may participate 
in the s tudy. Subjects with baseline  1+ or higher proteinuria are further  tested for 
albumin to creatinine ratio (ACR): 1) ACR ≤ 300mg/g may participate, 2) ACR 
>300mg/g  are excluded and receive referral to PCP . No repeat screening for 
proteinuria in subjects who have ACR  >300 mg/g will be done.  
Subject s who experience 1+ or higher proteinuria during t he study are further  
tested for ACR: 1) ACR ≤ 300mg/g may continue participation , 2) ACR >300mg/g 
permanently stop study drug  and receive referral to PCP  or nephrologist along 
with notification of the Medical Monitor . A referral to Nephrology is recommende d 
if ACR>1000mg/g. A kidney biopsy is recommended if proteinuria  >300  does not 
resolve within 6 weeks of drug cessation . 
b. Renal function monitoring:  Subjects with baseline eGFR  ≥ 60 may participate in 
the study. Subjects with baseline eGFR<5 0 are excluded.  Subjects with baseline 
eGFR 50 -59.9 are retested : 1) eGFR  ≥ 60 may participate in the study , 2) 
eGFR<6 0 are excluded.   
Subjects who experience eGFR 50 -59.9 during the study are retested within  1 
month: 1) eGFR  ≥ 60 may continue participation in the study , 2) eGFR<6 0 
permanently stop study drug and are referred to PCP . Subjects who experience 
eGFR< 50 during the study permanently stop study drug  and referred to PCP . 
Regardless of the eGFR, if the eGFR decreases by 25% or more compared to 
the baseline eGFR, t he Medical Monitor should be notified and should review the 
information to determine the next course of action.    
c. Liver function monitoring : Abnormal  liver laboratory results are graded according 
to the Common Terminology Criteria for Adverse Events v5.0 
(https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm ). 
 VA Central IRB Protocol Template – version 10/26/2012  Page 21 of 48 
 Subjects  who have stable and asymptomatic baseline Grade 1 abnormal 
laboratory liver values may, at the discretion of the site treating neurologists, 
participate in the study. Subjects who experience  laboratory abnormalities of 
Grade 1 during the study will be permitted to continue at the full dose  of study 
drug unless advised otherwise by the DSMB  or other monitoring entities .  
Abnormal l aboratory tests may be repeated immediately if laboratory testing error 
is suspected. Laboratory tests should be repeated within 1 month for any liver  
values reaching a Grade 2  or greater .  
If laboratory liver value(s) are still Grade 2 or greater by  1 month, the 
investigational drug will be reduced by 50% and levels checked again within 1 
month. The rationale is that liver -related abnormalities are often dose -dependent. 
If laboratory liver value(s) improve to Grade 1 or less , the study drug dose is then 
increased to the full dose. If the same subsequent laboratory value(s) worsen 
again at the full dose, the subject may continue for the study duration at the 50% 
dose as long as subsequent laboratory values do  not meet Grade 2 or greater 
levels . If subjects on a 50% dose demonstrate continued Grade 2  value(s) at a 
maximum of 1 month, subjects should stop the investigational drug. Those 
subjects for whom laboratory values do not improve to Grade 1 or better leve ls 
after 2 months off study drug permanently stop study drug . Only two 
investigational drug cessations are allowed for each subject. Any subject who 
experiences a third Grade 2 or higher laboratory test must permanently 
discontinue the investigational drug . If in question, permanent study drug 
discontinuations can be discussed with the Medical Monitor to establish the 
relationship of the laboratory result to the investigational drug. Subjects continue 
study procedures following the study flowsheet until stu dy end during any 
investigational drug dose reductions  and temporary  cessations (see 5.1d for 
special handling of MS clinical relapse evaluations).  
Safety laboratory results will be reviewed by site treating neurologists within 3 business 
days to determin e if dose adjustments or safety reporting is required along with 
documentation and reporting as required  (section 6.0 Reporting) . 
Sexually active female subjects capable of becoming pregnant and female partners of 
sexually active male subjects will be aske d to use effective birth control during the 
study. If a female participant or partner of a male participant becomes pregnant during 
the research study, study personnel must be notified immediately. Subjects will be 
advised not to breastfeed while taking th is investigational drug. Screening for pregnancy 
in female subjects of child -bearing potential will be conducted via pregnancy tests at 
study visits.  
 VA Central IRB Protocol Template – version 10/26/2012  Page 22 of 48 
 Because LA may increase the risk of hypoglycemia in diabetics, otherwise eligible 
subjects who are diabet ics must have their diabetes controlled on non -insulin 
medications. Safety monitoring labs at every visit for all subjects includes non -fasting 
blood glucose levels, and HbA1c levels.  
Because the risks of LA taken with DMTs are unknown, safety laboratory monitoring will 
screen for interactions affecting target organs. Subjects will be advised not to drink 
alcohol while taking the investigational drug and to store it out of reach of children.  
The risk of falls during gait testing will be minimized by havin g trained research staff 
present at all times during gait testing, and a gait belt will be utilized as needed. Gait 
testing will be aborted if there is concern for safety or falls by either the participant or 
research staff.  
Risks of MRI will be minimized by careful attention to MRI exclusion criteria at the 
screening visit including those who require non -oral sedatives during the scan. Any 
incidental findings unrelated to the study found on MRI such as brain tumors, stroke, 
etc., will be reviewed by the si te treating neurologist who will consider referral to the 
appropriate medical service, determine ongoing safety for the subject’s continued 
participation in the study, and to fulfil any reporting requirements necessary. Site 
treating neurologists will coun sel subjects with unexpected findings on MRI to minimize 
any psychological trauma incurred by the discovery.  
Overall, the risks of LA are considered minimal and are outweighed by the potential 
benefits to be gained by the study.  
5.1n.  Data banking : MRI an d images and analyses results along with subject 
demographics and medical histories will be banked in the VAPORHCS Biorepository for 
Neurological Diseases (BND #2916). The only PHI included in the data repository is the 
date of study visit. These dates are  necessary for the proper identification of images 
and data in subjects with multiple data entry points. The banking of the images is 
described in the Informed Consent Form (ICF).  
5.1o. Optional biorepository p articipation : All subjects who have consented to the 
LAPMS study will be asked if they would like to contribute their blood to the 
Biorepository for Neurological Diseases  (BND)  #2916 (Rebecca Spain, director , 
Portland, OR ). If the subject consents  to the blood donation, approximately 10ml (2 
teaspoons ) of the blood collected a t each study visit requiring a routine lab draw  will be  
saved for storage in the BND indefinitely for future research . A coded data set including  
study ID, date of specimen collection , study visit, sex, age at time of blood draw, 
education, diagnosis, dis ease duration, study arm, and comorbid health conditions is 
 VA Central IRB Protocol Template – version 10/26/2012  Page 23 of 48 
 also stored indefinitely with the donated blood . Subjects are allowed to start or stop 
participat ion in the biorepository at any time, however , per the consent for the BND , 
blood samples already provided to recipient  IRB-approved studies cannot be ext racted 
after donation .  
 
Subjects who consented to the LAPMS trial, prior to the addition of blood donation to 
the BND , will be asked to sign an updated consent indicating if t hey do or do not 
consent to adding their blood to the BND . Only subject s who  sign an updated ICF 
indicating agreement will have their blood included in the biorepository.  
5.2 Recruitment Methods  
5.2a.  Recruitment goal:  A total of 118 subjects will be recr uited for the study which 
include s an expected 25% will -drop rate out after enrolment. More potential subjects will 
be screened than enrolled as it is expected that some will not meet eligibility 
requirements despite screening meth ods. The PM and DCC will monitor recruitment 
across study sites and provide feedback on when enrolment is complete in order to stop 
recruitment (see Communication Plan 8.0).  Recruitment data and reasons for failing to 
enroll in the study will be collected periodically from all stu dy sites for the purpose of 
encouraging enrolment and identifying barriers to participation.  
5.2b.  Subject Identification/Recruitment : Potential subjects for the study will be recruited 
by the site study staff from MS clinics and from the general public  by methods approved 
by the study site’s local Institutional Review Board (IRB)  and/or a C entral IRB . Sample 
advertisement s recruitment flyers  (Appendix B ), recruitment letters to local MS 
practitioners  (Appendix C ), and telephone scripts for interested Veter ans and non -
veterans (Appendix D ) are provided to each site. E mail blasts to potential subjects will 
be sent from the National MS Society using the approved language contained in the 
recruitment flyers and letters  (Appendix E ). The NMSS promote s the study by hosting a 
webpage including a study summary , site locations,  and study coordinator contact 
information.  A short URL  (Appendix X), linking to the NMSS webpage, may be 
distributed during media interviews, and added to promotion materials  (Appendix Y) 
during MS related  events, such as but not limited to, MS Walks, MS races, and MS 
support groups.  ResearchMatch.org will be used as one of the recruitment tools for this 
research study/protocol. ResearchMatch Volunteers will be contacted through 
ResearchMatch.o rg using the approved language contained in the  recruitment message 
(Appendix W ). A release of information will be obtained as needed to request medical 
records for eligibility review prior to scheduling screening visits. Participants enrolled in 
the North  American Research Committee on Multiple Sclerosis ( NARCOMS ) registry for 
Multiple Sclerosis will receive an approved study flyer in the mail. As with other 
recruitment tools, a release of information will be obtained as needed to request medical 
 VA Central IRB Protocol Template – version 10/26/2012  Page 24 of 48 
 records f or eligibility review prior to scheduling screening visits.  We will make use of the 
contact information in Dr. Rebecca Spain’s MS Research Repository (IRB#18541). This 
repository contains names and contact information of people interested in research 
participation. All subjects included in the repository have consented to bein g contacted 
for opportunities for participation in research. Initial contact with potential participants 
will be made by the research coordinator. The CCC will also work with the Recru itment 
Innovation Center (RIC) at Vanderbilt University to implement a 4 -week, multicity, social 
media ad campaign in partnership with a marketing agency, R ed Deluxe.  Red Deluxe, a 
recruitment tool, will have 3rd party administrative access to a study Face book page, 
managed by the CCC, in order to monitor and push Facebook ads  to a targeted 
audience based on eligibility criteria and interest in MS.  Examples and text  of the 
components within the social media ad campaign include the Facebook page (Appendix 
Z), the Facebook Ads (Appendix  AA), and the study webpage (Appendix BB) and 
content (Appendix CC) , adhering to  the VA Graphic Standa rds Guide.  
5.2c.  Recruitment of specific subpopulations.  MS has a predilection for affecting 
women in a 3 -4:1 ratio. Therefore  we expect women to be adequately represented in 
this current study using a convenience sample. Minorities will not be preferentially 
recruited as there is no data to suggest a differential effect of LA on specific minority 
populations and/or with particul ar genetic characteristics. MS is rare in children, and 
progressive forms of MS rare within this small population. Therefore no children will be 
enrolled.  
5.2d.  Recruitment of Veterans : The pilot trial of LA recruited 21 Veterans from the 
total 51 subjects . The current proposed study has more restrictive inclusion criteria than 
the pilot study, requiring that subjects are ambulatory. Recruitment of non -Veterans and 
use of VA and non -VA study sites is necessary to fulfil the enrolment timeline.  
5.2e.  Sources  of materials : Sources from human subjects will include blood and urine 
samples and data in the form of clinical tests (e.g. gait, neurologic exam), patient -
reported outcomes, and radiographic information (MRI). Medical records will be 
reviewed prior to th e screening visit to assess for eligibility and confirm MS diagnosis. 
Data will be collected solely for research purposes.  
5.2f. Benefits:  Subjects may or may not benefit directly from the study. The benefits to 
society may be the discovery of a safe and  low-cost oral therapy to treat PMS.  
5.2g.  Costs to subjects:  There will be no cost to subjects to participate in this study. 
The study drug and investigations will be covered by the study budget.  
 VA Central IRB Protocol Template – version 10/26/2012  Page 25 of 48 
 5.2h.  Subject compensation:  Subjects will receive $50 per visit including unscheduled 
visits and $25 for extra laboratory visits if needed and cannot be performed locally. In 
addition, subjects are compensated for travel with $0.50/mile over 30 miles up to a 
maximum of $100 per visit. The payments will be in the form approved by each local 
study site, and will cover the costs of transportation and meals during the study visits. 
The compensation is included in the ICF. Subjects will be provided compensation after 
each visit regardless if all procedures are complete d. 
5.3 Informed Consent Procedures  
Subjects will be required to sign IRB - approved ICFs  in accordance with FDA Code of 
Federal Regulations (21 CFR 50). The ICF will be presented to all potential subjects at 
the screening visit by study personnel  who are tr ained in human subjects protection as 
required by the site IRBs . Briefly, the ICF describes the purpose of the study, 
procedures and participant involvement, potential risks, protection against risks, 
alternatives to participation, costs and compensation, confidentiality, right to withdraw, 
potential benefits, relevant contact personnel, and new information regarding the Health 
Insurance Portability and Accountability Act of 1996. Potential subjects will have ample 
time to read and ask questions, and, when satisfied, will document their consent to 
participate by signing the ICF. A copy of the ICF is given to the participant and the other 
retained for study records. All subjects must be able to provide informed consent in 
English.  Potential subjects with impa ired decision making ability will not be included in 
the study as they may not be able to adhere to study procedures per the eligibility 
requirements.  
5.4 Inclusion/Exclusion Criteria  
Inclusion criteria:  
i. Age > 18 years.  
ii. Previous diagnosis of RRMS or PPMS by 2010 revised McDonald criteria. (20) 
iii. Current SPMS or PPMS.  
iv. Progression of MS in the previous 2 years defined by medical rec ord or reliable 
historical interview as:  
a. Non relapse -related MS decline resulting in a 0.5 step change in EDSS, 
decline in T25FW, or other clinically documented decline (can be assigned 
retrospectively) if not on a DMT, OR  
b. If currently on a DMT, non -relaps e-related MS decline resulting in a 0.5 
step change in EDSS, decline in T25FW, or other clinically documented 
decline (can be assigned retrospectively) while on the current DMT taken 
continuously for at least 1 year prior to enrolment.  
 VA Central IRB Protocol Template – version 10/26/2012  Page 26 of 48 
 v. Able to give informe d consent and to adhere to study procedures.  
vi. EDSS 3.0 to 6.5.  
 
Exclusion criteria:   
i. A self -reported medical or neurological problem other than MS that is a cause of 
progressive or fluctuating gait dysfunction (e.g. worsening neuropathy, 
uncontrolled lower extremity arthritis, uncontrolled cardiopulmonary disease). 
Fixed and/or stable conditions of greater than 1 year that affect their gait are 
permitted (e.g. joint replacement, stable lumbar stenosis, remote alcoholism, 
remote stroke, etc.).  
ii. MRI constraints  (metal implants including pacemaker, devices with electrodes, or 
shrapnel, excessive weight per site MRI requirements, need for sedation with 
non-oral agents due to claustrophobia or muscle spasticity).  
iii. MS clinical relapse in the 1 year prior to enrolment . 
iv. Unable to follow directions in English as standardized scales are not all validated 
in other languages.  
v. Current major disease or disorder other than MS (e.g., cancer, renal disease, 
end-stage cardiopulmonary disease, post -traumatic stress disorder, etc. ) that 
may interfere with study procedures. Stable abnormal laboratory values of no 
more than Grade 1 determined to not be of clinical significance to the primary 
treating physician for that condition may be permitted per LSI discretion  and 
comply with spe cific renal and liver testing requirements described in section  
5.1m . 
vi. Pregnant or breast -feeding.  
vii. Insulin -dependent diabetes or diabetes not controlled on oral diabetes 
medications.  
viii. Scheduled (every 3 months or more frequently) IV or oral steroids in the y ear 
prior to enrolment.  
ix. IV or oral steroids in the 60 days prior to enrolment.  
x. Use of LA in the prior 2 years exceeding the equivalent of 1200mg daily for 3 
months.  
xi. Participation in the pilot LA in SPMS trial.  
 
 
 
 
 VA Central IRB Protocol Template – version 10/26/2012  Page 27 of 48 
 5.5 Study Evaluations  
5.5a.  Study flowshe et 
Procedure  Screen  Baseline  
M 0 M 3 M 6 
M 12  
M 18  M 24  
Consent  X     
Medical history  X     
General medical exam  X     
Inclusion/Exclusion review  X X    
Safety labsab X Xc X Xh X 
Randomization   Xg    
Vital signs  X X X X X 
Concomitant Medications  X X X X X 
T25FW  X X  X X 
9 HPT  X X  X X 
2MTW  X X  X X 
EDSS  X X  X X 
Cognitive 
tests  SDMT   X  M12 only  X 
CVLT -2ed  X  M12 only  X 
BVMT -R  X  M12 only  X 
Patient 
reported 
outcome 
measures  PROMIS – pain intensity   X  X X 
PROMIS – pain 
interference   X  X X 
PROMIS - participation in 
social roles   X  X X 
PHQ -9  X  X X 
 VA Central IRB Protocol Template – version 10/26/2012  Page 28 of 48 
 SS-MOS   X  X X 
MFIS   X  X X 
FESI   X  M12 only  X 
GLTEQ   X  X X 
Fall count    X  X 
MRI  Xe   Xe 
SBQ -R X X X X X 
Adverse event monitoring & compliance 
reviewd  X X X X 
Investigat ional drug dispens ing  X X X  
Subject/provider blinding questionnaire      X 
Subject compensation  X X X X X 
Subject dispositionf     X 
Length of visit (hours)  3 4 1 3 4 
BVMT -R, Brief Visuospatial Memory Test - Revised ; CVLT -2ed, California Verbal 
Learn ing Test - Second Edition; EDSS, Expanded Disability Status Scale; FESI, Fall 
Efficacy Scale -International; GLTEQ, Godin Leisure -Time Exercise Questionnaire , 
modified;  MRI, magnetic resonance imaging; MFIS, Modified Fatigue impact Scale; 9 
HPT, 9 Hole Peg T est; PHQ -9, Patient Health Questionnaire -9; PROMIS, Patient 
Reported Outcome Measures Information Systems; SBQ -R, Suicide Behaviors 
Questionnaire -Revised ; SDMT, Symbol Digit Modalities Test; SS-MOS, Sleep Scale 
from the Medical Outcomes Study;  T25FW, Timed  25 Foot Walk; 2MTW, 2 Minute 
Timed Walk  
aIncludes pregnancy test for female subjects of childbearing potential only  
b Optional Biorepository #2916 participation 
cOnly pregnancy test for  female subjects of childbearing potential . 
dOccurs at study visits and approximately halfway between each visit after baseline by 
telephone calls  
eMRIs scheduled up to 14 days prior to M0 and up to 14 days prior to M24 visits. MRIs 
can be same day as M0 a nd M24 visits.  
 VA Central IRB Protocol Template – version 10/26/2012  Page 29 of 48 
 fOccurs at visit M24, at final visit for early termination, and when a subject is determined 
lost to follow -up. 
gMay occur prior to M0 visit day, when appropriate for logistical purposes, to avoid 
excessive M0 study visit times.  
hUrine prote in additionally tested M9, M15, M21.  
5.5b.  Consent, medical history, general medical exam : The ICF will be presented by 
the PI, LSI, or designated study staff. After consent has been obtained, the rest of the 
study procedures can occur. The medical history  and general medical exam is 
conducted by the treating neurologist for the purpose of eligibility.  
5.5c.  Vital signs:  Resting blood pressure, pulse, and weight are collected by trained 
study staff at every study visit for the purpose of initial eligibilit y and ongoing health 
monitoring. Consistent methods of obtaining data (e.g. same resting period prior to 
blood pressure and pulse assessments, etc.) is encouraged across study visits. Height 
is assessed at the screening visit only.  
5.5d.  Concomitant medica tion review:  Current use of prescribed scheduled and as 
needed medications as well as over the counter medications and supplements is 
recorded by the study staff and reviewed at the screen visit by the treating neurologist 
for study eligibility. Concomitan t medications are reviewed at each subsequent visit by 
study staff and changes reviewed by the treating neurologist. Any start, stop, or change 
to MS disease -modifying therapies will be noted and dated for data analysis purposes. 
Supplements will be review ed by research staff in case they contain lipoic acid or other 
potential confounders to the study results.  
5.5e.   Safety laboratory analyses:  Laboratory studies will be collected from all subjects 
at the screening visit if not available within the prior 3 months for establishing eligibility. 
Additional laboratory analyses occur at visits M3, M6, M12, M18 and M24 to monitor 
blood cell count, renal function, liver function, urine protein, non -fasting blood glucose 
levels, HbA1c, and (for women of child -bearin g potential) pregnancy testing.  Subjects  
must have urine protein monitored every 3 months for the duration of the study .  
Pregnancy testing is additionally conducted at the baseline visit for women of child -
bearing potential. This involves taking approxima tely 15 -25 mL (3 to 5 teaspoons) of 
blood at each draw for a total of 90 -150mL (2/3 cup) over the course of the study. 
Laboratory draws will be performed by trained phlebotomists using universal 
precautions.  
5.5f. Inclusion/Exclusion review:  Eligibility cr iteria are reviewed by the treating 
neurologist during the screening visit. Once all criteria are met  and confirmed at the 
baseline visit , the study staff will use REDCap to assign a randomization code and  then 
 VA Central IRB Protocol Template – version 10/26/2012  Page 30 of 48 
 request study drug using the blinded randomiz ation code.   For logistical purposes, this 
may occur prior to M0 visit day to avoid excessive M0 study visit times. Each site 
pharmacy will then dispense the drug according to the assigned treatment on the 
randomization schedule, which will be located at e ach site pharmacy.  Subject  screens 
who do not meet inclusion/exclusion requirements will be accounted for in the 
recruitment monitoring process (See 5.2 Recruitment Methods).  
5.5g.   Walking tests.  The T25FW  and 2MTW  will be collected at the screening and 
baseline visits, and every 6 months during the study (21, 22) . For the T25FW, subjects 
are instructed to walk 25 feet marked on the ground “quickly but safely” (Appendi x F). 
The measure is immediately repeated and th e two results averaged. Assistive walking 
devices including canes and walkers are permitted. The 2MTW determines the distance 
a participant walks in 2 minutes. Dalfampridine is an FDA -approved symptomatic 
treatment for improving walking speed in MS. Subjec ts will be asked to maintain their 
usual dose of dalfampridine at all study visits . Subjects will be strongly encouraged to 
use the same assistive devices (insoles, orthotics, canes, walkers, etc.) if used at the 
study start throughout the remainder of the  study as safely possible. Subjects who 
become unable to complete the mobility testing during the course of the study due to 
worsening MS will continue the study and be analyzed as having worsening mobility 
according to the data analysis plan. Subjects who  are unable to complete mobility 
testing for non -MS related reasons will not have data recorded for that study visit. 
Because gait testing is the primary outcome measure, subjects should be tested as 
early as possible during each study visit. Testing condi tions should be as uniform as 
possible from visit to visit (see 5.1 Study Design, Study timeline and visit scheduling).  
5.5h.   EDSS: The EDSS is an eight functional system scale to assess overall MS 
disability including motor, sensory, cerebellar, brain s tem, visual, mental, sphincteric, 
and other systems (24). Each functional system is graded  from 0 (no disability) to 5 or 6 
(maximal disability). An integrated score between 0 (normal examination) and 10 (death 
from MS) is formed based on the score in each functional system. The EDSS exam will 
be performed by a blinded and trained EDSS examiner  who is not the subject’s usual 
treating neurologist (Appendix G ). 
5.5i.  9HPT:  The 9 Hole Peg Test (9HPT) is a timed test of upper extremity arm and 
hand function. Subjects place pegs into a platform with hole and then take them out 
again (Appendix F). The 9HPT and T25FW will be administered in accordance with the 
instructions for the Multiple Sclerosis Functional Composite (21). 
5.5j.  Cognitive tests : Cognitive testing will utilize the Brief International Cognitive 
Assessm ent for MS (BICAMS (25) which includes  the Symbol Digit Modalities Test (26) 
(Appendix H ), the California Verbal Learning Test - Second Edition (27) (Appendix I ), 
 VA Central IRB Protocol Template – version 10/26/2012  Page 31 of 48 
 and the Brief Visuospatial Memory Test - Revised (28) (Appendix J ). These measures  
will be assessed at baseline, M12 and M24.  
5.5k.   Patient -reported outcome measures:  The Patient Reported Outcome Measures 
Information Systems (PROMIS) will pain intensity  (Appendix K ), pain interference  
(Appendix L ), and ability to participate in social roles (Appendix M ) (29). Additional 
measures of depression (Patient Health Questionnaire -9, Appendix N ), sleep the 
previous 4 weeks (Sleep Scale from the Medical Outcomes Study , Appendix O ), 
exercise (Godin Leisure -Time Exercise Questionnaire , modified , Appendix V),  and the 
Modified Fatigue impact Scale  (Appendix P) will be administered at baseline and every 
6 months thereafter (30, 31) .  The Fall Efficacy Scale -International (FESI) (Appendix T ) 
is administered annually.  
5.5l.  Fall count : Fall count will be kept by a daily Fall Count Diary (Appendix Q). Each 
calendar page will cover 1 month and will include space to count falls and fall -related 
injuries each day. Each page wil l include the definition of a fall as “any unexpected 
event that results in you ending up on the ground, floor, or any lower surface” (23). At 
the baseline visit, subjects will be given calendars to cover the first 3 months. Subjects 
will be called  once at the between visit  telephone call  to encourage falls calendar 
reporting and have the opportunity to answer any fall counting related questions. A final 
3 month supply of falls calendars will be mailed before the end of the study with a target 
start date on the calendar corr esponding to 3 months prior to the final study visit. 
Subjects will again be called once to encourage compliance and answer any related 
questions.  
5.5m.  MRI procedures .  
a. MRI acquisition protocol:  A 3T MRI will be utilized to acquire the following series 
of the brain. 1. A high resolution Magnetization Prepared Rapid Acquisition 
Gradient Echo (MPRAGE) for high resolution structural (T1 -weighted) 
information, as the basis for brain atrophy measures. Partitions will be 1.0 mm; 
voxels 1 mm3. 2. Conventional bra in imaging with T2 -weighted, and FLAIR 
series; 2mm (non -gapped) slice acquisition, with in plane resolution 1mm2. 
Intravascular MR contrast will not be administered. 3. The American College of 
Radiology phantom scan will be utilized as necessary for qualit y control. The 
imaging procedure will require 60 minutes with approximately 30 minutes 
participant scan acquisition time, 10 minute phantom scan acquisition time (when 
needed), and the remaining 20 minutes for positioning and questions. Careful 
screening o f subjects prior to MRI will be done to reduce the chance of injury due 
to MRI -contraindicated conditions.  
b. MRI clinical readings.  MRIs will receive a clinical read from site clinical radiology 
staff and results reviewed by site treating neurologists for co ncerning findings 
 VA Central IRB Protocol Template – version 10/26/2012  Page 32 of 48 
 (tumor, stroke, etc.) which, if found, will be communicated to the appropriate 
clinical service for optimal management including treatment of MS exacerbations.  
c. MRI volumetric analyses:  MRI analyses used for study outcomes will be 
analyzed  by the Central MRI Reading Site at OHSU. MRI images are sent to the 
Reading Site via secure methods. Prior to analyses, AIRC staff will ensure that 
only the study ID and PHI element of date of study visit are visible to the analysts 
to reduce any bias. Brain volume measures will be based on SIENAX software 
and brain atrophy measures on SIENNA tools in the FSL software library 
produced by the Oxford Centre for Functional MRI of the Brain (32). Total brain 
T2-hyperint ense lesions will be determined using in -house software. In -house 
and FSL software will be used to explore differential gray versus white matter 
atrophy as an exploratory MRI outcome measure. Study MRIs will be reviewed 
for quality within 2 weeks of receip t in order to rescan a subject  (1 rescan per 
subject per MRI visit permitted) if needed w ithin an acceptable time -frame.  
d. MRI quality control (QC):  In order to ensure high quality and comparable images 
across study sites, the Central MRI Reading Site will coordinate QC by having 
each site perform test scans prior to study start and after every scanner upgrade 
during the study to review for image quality. In addition, each site will conduct 
standard phantom scan according to protocols set by the American Col lege of 
Radiology. Feedback from the Central MRI Reading Site staff to the study sites 
regarding test, phantom QC, and study MRIs will occur in a timely manner so that 
errors can be fixed promptly.  
5.5n.   Suicidality monitoring:  Monitoring suicidality is a requirement by the Food and 
Drug Administration for all neurology studies involving an IND. Monitoring using the with 
the Suicide Behaviors Questionnaire -Revised  (SBQ -R) occurs at the screen to establish 
a baseline and every subsequent study visit to eva luate for the developmen t of new 
suicidality (Appendix R). 
5.5o.  Adverse event (AE) monitoring:  This occurs at baseline, every subsequent visit, 
at between visit telephone calls, and ad hoc . Unscheduled visits will occur to evaluate 
AE per the protocol gui delines (sec. 5.1d). AE are coded by the DCC  according to 
MedDRA  and reported per the reporting guidelines (sec. 6.0).  
Subjects will be encouraged to remain in the study through study completion if they 
start, stop, or switch a DMT, if their disability pro gresses due to MS to an EDSS of more 
than 6.5, or if they have an MS relapse. Subjects who develop MRI contraindications 
may continue through the study end without further MRIs. Study staff will review 
eligibility at study visits and during regularly sched uled meetings.  
 VA Central IRB Protocol Template – version 10/26/2012  Page 33 of 48 
 5.5p.   Investigational drug dispens ing: Drug dispens ing occurs at baseline and every 
study visit according to dispens ing schedules by the site research pharmacies.  
5.5q.   Subject/provider blinding questionnaire:  All blinded study staff and s ubjects take 
a blinding questionnaire at M24 to evaluate the blind  (Appendix S). 
5.5r. Subject disposition form : Final disposition of each subject is recorded on this form 
at the M24, early termination visit, or when determined that the subject is unable t o 
attend an early termination visit.  
5.6 Data Analysis  
5.6a.  Sample size : The sample size and power analysis were based on the pilot LA in 
SPMS trial in which LA had improved time to complete the T25FW ( -0.54 seconds SD 
0.36 vs 0.14 SD 0.25, p = 0.06). A s ample size of 44 per group will have 80% power to 
detect a difference between the LA group with a coefficient, β 1 regression slope of -0.50 
seconds and the placebo group coefficient, β 2 slope of -1.00, assuming that the 
standard deviation of the difference  between the groups is 2.20 and the standard 
deviation of the residuals (repeated measures within each participant) is 1.80 with a 
0.05 two -sided significance level and the correlation of 0.85 between the measurements 
over time, which if lower increases th e power. The delta of improvement is a reduction 
in the rate of walking slowing of 0.5 seconds per unit of time.  This translates into 2 
seconds on the average timed walk over 2 years.  A sample size of 59 per arm will allow 
for a 25% drop -out rate.  The pilo t study had a 10% drop out rate however 25% is more 
realistic for a multi -site trial in an era with more therapeutic options for MS. Screen visit 
failures are likely to be minimal (<10% of all screen visits) as most eligibility 
requirements can be made pri or to the screening visit using the methods described in 
5.2 Recruitment Methods.  
As a check on these calculations we compared the estimates, Altmann et al.’s estimates 
of sample size when using SIENA as the method of determining whole brain atrophy 
rate, the current sample of 44 per group will achieve 80% power at significance level 
0.05 assuming a 40 -50% effect size (33).  
5.6b.  Data analysis plan:  Data is analyzed by the SCC at study completion or at 
any point req uested by the DSMB. Only subjects that complete the baseline 
evaluation and take at least one dose of study drug will be included in the data 
analysis.  
The SCC  will use the mixed model approach to compare, between the treatment 
groups, mean rates of change  from baseline in the times to complete the T25FW. The 
SCC  will use the transformation 25/T25FW, which is the walking speed in feet per 
 VA Central IRB Protocol Template – version 10/26/2012  Page 34 of 48 
 second. In constructing these models for the T25FW walking speed outcome, baseline 
disability will be incorporate d as a predictor. The primar y outcomes is whether there is a 
difference between the treatment groups in the T25FW rate changes. Given evidence of 
interaction, comparisons of both 12 and 24 month change between the treatment 
groups will be made, using a Bonferroni  multiple comparison adjustment for two time 
points of interest. Additional models will include as covariates, baseline measures of 
disease duration and use of MS medications if significantly related to the response 
when added to the original model or resu lt in a 10% change or greater in the estimated 
overall treatment effect. Secondarily, the SCC  will compare with a t -test or 
nonparametric tests the proportion of participants who demonstrate clinically significant 
worsening in gait defined by a 20% improve ment in the T25FW and/or 2MTW and/or 
requires greater assistance to walk (e.g. newly require a cane, transition from cane to 
walker, etc.). A sensitivity analyses  will be performed  using an intention to treat analysis 
with the cross -over with and without p articipants who have a change in their disease -
modifying therapy during the course of the study. Compliance information will be added 
as determined by pill -counts to the mixed model.  
The impact of LA on falls frequency will be assessed by comparing change s in fall 
frequency from the first to the last 3 months. A principal intention -to-treat analysis using 
linear Poisson mixed models to evaluate the association between time period, fall 
frequency, and group allocation will test the hypothesis that fall freq uency is reduced 
more by LA than placebo. Mixed models will be used to correct for autocorrelation of 
within -subject repeated measures and allow for missing data, and include covariates 
associated with falling such as age, level of disability, and use of a  walking aid. As 
exploratory secondary outcome measure, the SCC  will investigate the disconjugate 
composite endpoint based on sustained change in EDSS, clinically significant 
worsening in gait as defined above, or 20% increase in 9HPT.  
The mixed model appr oach will compare the mean rates of change from baseline in 
brain as measured by SIENA . Age, sex, and disease duration will be used as covariates 
along with disability.   
Adverse and serious adverse events will be tabulated and compare the differences in 
the occurrence and the frequencies between the two groups. The frequency of side 
effects will be compared using χ2 tests or Fisher’s exact test as appropriate depending 
on the number of adverse events seen.  For evaluation of patient safety, laboratory test 
results at baseline and changes from baseline will be summarized and compared using 
t-tests for continuous measures and Fisher’s exact test for proportions.  
 
 
 VA Central IRB Protocol Template – version 10/26/2012  Page 35 of 48 
 5.7 Withdrawal of Subjects  
Subjects can withdraw from the study at any time. Reason for withdraw al will be recorded. 
Subjects may also be withdrawn from t he study by LSIs and in agreement with the study 
PI for any of the following reasons: 1. New or worsening medical conditions (e .g., cancer, 
renal disease, end -stage cardiopulmonary disease, post -traumatic stress disorder, 
uncontrolled diabetes, etc.) that may interfere with study procedures or otherwise pose 
concern for subject health or safety, 2. New pregnancy, 3. Inability of subjects to comply 
with study procedures, 4. Other reason s deemed import ant to subject safety or data 
quality raised by the DSMB, IRB, FDA, or any other regulatory body that has the authority 
to do so.  If subjects are deemed no longer safe to take the investigational drug but 
otherwise are able to participate in the study outc omes for the remainder of the study, they 
are encouraged to do so.  
Female study subjects of childbearing potential will be encouraged to use effective birth 
control methods during the study. Pregnancy testing in female subjects of childbearing 
potential wi ll be conducted as part of safety laboratory studies at each study visit according 
to the study flowsheet. Should pregnancies occur during the study, those female subjects 
will be withdrawn from the study. I nformation will be collected as to the pregnancy course, 
outcome and health of the newborn infant. Because LA is available as an over the counter 
supplement, male subjects whose female partners become pregnant will continue in the 
study, however pregnancy and birth outcomes of the female partners will be  recorded and 
presented to the DSMB.  
If a subject wants to withdraw from the study, the subject will contact the site study staff 
using the contact information and procedures on the ICF and request withdrawal. If a 
subject withdraws or is removed from the  study for any reason  and is unable or 
unsuitable to continue the study procedures off investigational drug , the reason and 
date of discontinuation of the investigational drug  is recorded. At the time of study 
discontinuation, every effort will be made to schedule  the subject for an early 
termination visit following the procedures for  M24 without the MRI or F all Count D iary if 
termination is within 6 months of the baseline visit, and M24 proce dures with MRI but 
without fall count  if termination is greater t han 6 months of the baseline visit . Subjects 
withdrawn due to reportable adverse events and subjects with adverse events thought 
related to the study that are ongoing at the final study visit are followed for 30 days or 
until resolved, whichever is first, or longer per request of the Medical Monitor.  
 
6.0 Reporting : All SAE, UAP, and PD are reported to the IRB within defined 
timelines.  
 
 VA Central IRB Protocol Template – version 10/26/2012  Page 36 of 48 
 6.1 Adverse event reporting  
Adverse event (AE) information will be monitored in detail throughout the course of the 
study.  AEs are  defined as and will be graded as to their expectedness and attribution 
(unrelated,  possibly, probably, or definitely related to the protocol). Dr. Mary Samuels 
will act as the medical monitor to determine relationship of AEs to the study intervention 
if uncertain. AEs will be reviewed by site treating neurologists, graded, and reported to 
the DCC . The DCC will code  the events using MedDRA  and will assist the CCC with 
IRB reporting  per reporting guidelines.   
6.2 Limited collection of non-serious AE 
Some AEs are  expected, so a limited set of AEs will be collected for this trial. Upper 
respiratory and urinary tract infections will not be tracked or reported, unless they reach 
an intensity of severe . Gastrointestinal distress is a known side effect of LA. Therefore  
only GI distress related and probably related to study of any intensity is  tracked and 
reported.  All other AEs are collected and stored at the study sites.  
 
6.3 Limited reporting of AE  
Not all AE captured at sites are reported to the DCC. The limited set of A E reported to 
the DCC via the REDCap database is according to guidelines in 6.3a below . Serious AE 
(SAE)  and select UP and PD  are reported under expedited guidelines according to IRB 
and other monitoring entity requirements.  
 
6.3a Limited r eporting of AE , UP, and PD  to the DCC . Bold items require expedited 
reporting to the DCC via REDCap.  
AE Intensity*  AE related  to 
study  AE probably 
related  to 
study  AE possibly 
related  to 
study  AE unrelated  
to study  
Mild REDCap  AE Log only  AE log only  AE log only  
Moderat e REDCap  RED Cap AE log only  AE log only  
Severe  REDCap  REDCap  REDCap  REDCap  
SAE  REDCap  REDCap  REDCap  REDCap  
UP with risk to 
subjects or 
others  REDCap  REDCap  AE log only  AE log only  
Severe PD: REDCap  Moderate PD: REDCap.  Mild PD: AE log only  
* Increas es after Screen in CTCAEv5 grades (ALT, AST ), new ACR >300mg/g,  and new 
eGFR<60 are always reported in REDCap regardless of intensity or relationship to study.  GI 
distress related and probably related to study of any intensity is reported in REDCap.  
 
ALT, Alanine Aminotransferase; AST, Aspartate Aminotransferase; ACR, Albumin to creatinine ratio  
 VA Central IRB Protocol Template – version 10/26/2012  Page 37 of 48 
 6.4 Adverse event (AE) definition : Any untoward or undesirable, a lthough not  
           necessarily unexpected, event experienced by a human subject that may be a  
           result of:  
• The interventions and interactions used in the research.  
• The collection of identifiable private information in the research.  
• An underlying disease, disorder, or condition of the subject.  
• Other circumstances unrelated to the re search or any underlying disease, 
disorder, or condition of the subject.  
6.5 Serious Adverse Event (SAE) definition : Any AE that:  
• Is fatal.  
• Is life -threatening.  
• Is persistent or significantly disabling or incapacitating.  
• Results in inpatient hospit alization or prolongation of hospitalization.  
• Results in psychological or emotional harm requiring treatment.  
• Creates a persistent or significant disability.  
• Causes a congenital anomaly or birth defect.  
• Results in a significant medical incident (co nsidered to be a serious study  
  related event  because, based upon appropriate medical judgment, it may  
  jeopardize the subject and may require medical or surgical intervention to     
  prevent  one of the outcomes listed in this definition).  
6.6 Unantic ipated problem (UP)  definition : 
• Any event that is not expected given within the context of the study.  
• Any event that places subjects or others at a greater risk of harm or 
discomfort relative  to what was previously known.  
• No harm to a subject needs t o occur for an event to be an unanticipated   
problem.  
 
6.7 Protocol Deviation (PD) : The term “protocol deviation” is not defined by 
either the HHS human subjects regulations (45 CFR 46) or the FDA human 
subjects regulations (21 CFR 50). All PD are graded b y the treating neurologist 
and entered into REDCap. Severe PD have expedited reporting to the DCC via 
REDCap.  Moderate PD are entered into REDCap according to the usual 
timelines. Mild PD are recorded on the site AE log only.  
 
6.7a.  Mild PD:  
• The deviation  resulted in no harm or risk of harm to research participants; or  
• The deviation did not result in or require any substantive action to be taken or 
result in a substantive change to the subject ’s condition or status (i.e., did not 
 VA Central IRB Protocol Template – version 10/26/2012  Page 38 of 48 
 affect the subject’s parti cipation in a substantive way, did not result in a change 
to the subject’s emotional or clinical condition, did not cause an adverse 
experience or require a change to the clinical care of the subject, etc.)  
• The deviation had no substantive effect on the v alue of the data collected (i.e., 
the deviation does not confound the scientific analysis of the results);  
• The deviation did not result from willful or knowing misconduct on the part of the 
investigator(s);  
• The deviation is easily corrected (e.g., consen ting a subject with an old version of 
an ICF, recording data on an expired/incorrect form, forgetting to record data that 
may be acceptably recorded at the next visit, etc.)  
 
6.7b.  Moderate  PD: 
• The deviation resulted in a harm or risk of harm that is not significant; or  
• The deviation resulted in the need for minimal risk interventions, such as those 
defined in 45CFR46.110 and 21CFR56.110;  
• The deviation resulted in the loss or improper collection or recording of some 
data for one or more subjects, but did  not invalidate the entire data set for the 
study;  
• The deviation resulted in a regulatory violation that can be acceptably resolved;   
• Repeated minor protocol deviations from the same laboratory, site or research 
team; or  
• There has been a failure to foll ow action ordered to correct minor or moderate 
protocol deviations . 
 
6.7c.  Severe  PD: 
• The deviation resulted in or required a substantive action to be taken or resulted 
in a change to the subject’s condition or status;  
• The deviation has significantly harm ed or posed a risk of significant harm to 
research participants;  
• The deviation has substantially damaged the scientific integrity of the data 
collected for the entire study;  
• The deviation is evidence of willful or knowing misconduct on the part of the 
investigator(s);  
• The deviation involves serious or continuing noncompliance with federal, state, or 
local research regulations;  
• There have been repeated minor and/or moderate protocol deviations from the 
same laboratory, site or research team;  
• There has be en a failure to follow action ordered to correct minor and/or 
moderate protocol deviations;   
 VA Central IRB Protocol Template – version 10/26/2012  Page 39 of 48 
 • There has been a failure to follow action ordered in accordance with the 
emergency action provision of this policy.  
6.8 Data a nd Safety Monitoring Plan   
Data and  safety monitoring will involve AE reporting by site study staff, and review of 
AE, SAE, UP, protocol deviations ( PD), dropouts, complaints , or breaches of 
confidentiality  by the DCC . Subjects will be encouraged to report any study -related 
and/or health pr oblems at any time to the study site staff. AEs reported to the DCC and 
other data and safety issues  found during site visit audit s will be subject to additional 
reporting (IRB, FDA) per reporting  policies.  
 
A Data Safety Monitoring Board (DSMB) will be a ssembled for subject safety. This 
board will consist of members who have expertise in any of the following: neurology, 
multiple sclerosis , clinical trials, and medical safety. The board members will document 
their lack of conflict of interest and approve a  DSMB Charter prior to study start. All 
members of the DSMB will review and approve study protocol and informed consent 
forms for all study sites prior to enrollment.  
 
The DSMB Chair or DSMB member designee reviews SAE in real time according to 
reporting t imetables (6.0). The DSMB receive s quarterly reports, developed by t he DCC 
and SCC , which include s aggregate reports of AE, SAE, UP, and PD, including the 
safety lab data according to Limited Reporting of AE (6.3) presented grouped by study 
arm and study s ite (as necessary).  The board will meet  every six months , as necessary, 
to review quarterly reports, enrollment/screening progress, data collection problems, 
and missing data. No non -safety related study outcome analyses will be performed until 
study compl etion, unless the committee determines there is a compelling reason to do 
so related to patient safety concerns. The DSMB also meet s when the last subject 
completes participation. The DSMB will provide a written summary of each meeting to 
the PI with a sta tement about appropriateness of continuation of the study.  DSMB 
report s are communicated at least annually to the Central IRB and non -VA IRBs.   
 
7.0 Privacy and Confidentiality  
7.1. Protected h ealth  information  (PHI)  
Study subjects  will be given a unique study ID t hat will be linked to the name and 
contact information by a key . The key will be  held by the LSIs for their site subjects , and 
for all subj ects by the PI. Local sites may collect PHI elements including name, address, 
email address, telephone numbers, dates  of birth, social security numbers, and medical 
record numbers for the purpose of recruitment, screening potential subjects, scheduling, 
 VA Central IRB Protocol Template – version 10/26/2012  Page 40 of 48 
 and creating site medical charts. These identifiers are necessary to avoid duplication of 
recruitment and screening eff orts and to ensure that the correct study procedures such 
as laboratory assessments and MRIs a re performed  at the local sites.  Dates of study 
visit will be  the only PHI element recorded in the REDCap study  database, the only PHI 
viewed by the SCC, and the only PHI retained in the data repository (BND #2916). PHI 
will be  transmitted on MRIs to the Central MRI Reading Site in order to properly identify 
the scans. The PHI elements may include date s of study visit s, name s, date s of birth, 
social security number s, and medical record number s. Prior to analyses and to ensure 
blinding, s taff at the Central MRI Reading Site will ensure that only the subject ID along 
with the PHI element of date of study visit are visible to the MRI analysts.  This is 
outlined on the ICF. All other PHI including names, addresses, contact information and 
medical records will be managed according to the procedures below.  
7.2 Privacy and Confidentiality  
Privacy of subjects will be maintained by obtaining and storing the minimum necessary 
PHI for the purposes of screening, enrolling, and maintaining  subject participation. 
Study data will be seen only by study staff authorized to do so . 
7.3 Information and specimen m anagement  
Subject data, initially identifiable when obtained, will be coded and d ated according to the 
date of study visit. The key to the code will  be maintained by each LSI and available to the 
study PI. Hard copies of study data will be stored in on -site locked cabinets, and electronic 
data stored on secure servers according to the privacy regulations of  each study site.  
Trained and designated study staff will enter s tudy data , from each site  and the Central 
MRI Reading Site , into a web-based REDCap database . OCTRI's REDCap software is  a 
highly secure and robust web -based research d ata c ollection and management system, 
which is physically housed on servers located in the OHSU’s Advanced Computing 
Center.  The servers are housed behind both the OHSU fire wall and a second ACC 
firewall.  All web -based data transmissions are encrypted with  industry -standard SSL 
methods.    
REDCap is a robust multi -level security system that will enable the PM and study PI to 
easily implement "minimum necessary" data access for their research staff, including 
specification of data fields that are identifiers.  The only PHI entered into REDCap will be 
the dates of study visits. Study sites will maintain up -to-date study staff personnel lists so 
that REDCap access is limited to approved study staff. User activities are logged to 
enable auditing of all data access . REDCap is jointly managed in accordance with 
OHSU Information Security Directives by ACC staff and members of OCTRI's 
 VA Central IRB Protocol Template – version 10/26/2012  Page 41 of 48 
 Biomedical Informatics Program, ensuring fidelity of database configuration and back -
ups.   
Hard copies of study data containing PHI  will be sent, when necessary,  through secure 
methods. For VA to VA transmission, this can include email using PKI or RMS encryption. 
Otherwise, transmission is via secure fax or secure mail such as FedEx/UPS with tracking. 
MRI images will be sent to the Centr al MRI Reading Site by secure electronic methods as 
allowed by OHSU and the sending institution such as an  sftp account, or on compact disks  
by secure mail such as FedEx/UPS with tracking.  
Study data manage ment is under the oversight of the  DCC . Members o f the DCC will have 
REDCap access to view, enter and edit data, and update the REDCap database 
throughout the study for the purposes of quality control. The DCC will work with the PM 
and site study staff to resolve data discrepancies in an ongoing fashion throughout the 
study.  
Blood samples for subjects participating in the optional BND are shipped to the VA 
Portland Health Care System via s ecure mail, such as FedEx/UPS with tracking . The only 
PHI on the specimen label is the date of  specimen collection . An electronic copy of 
coded data that does not contain protected health information, except for the date of 
specimen collection, will be transferred to the BND for storage via methods allowed by 
the VA and the sending institution , such as an sftp account, o r on compact disks by secure 
mail. 
The BND  is located at the VA Portland Health Care System in Portland, Oregon, in VA 
Building 101, Room 434 which is secured by card access  only. An electronic copy of 
coded data  is stored on secure VA networks located beh ind VA firewalls.  Dr. Rebecca 
Spain, director of the biorepository, makes the decisions regarding how the blood 
samples and data are used in the future under IRB -approved protocols . Samples from 
the biorepository released to other investigators may  include  the date of specimen 
collection . 
The ICF and HIPAA authorization provide  information about how specimens will be 
transferred, how long they will be kept, and who will view/use the specimens. Subjects 
who consented to the LAPMS study prior to the addition of the option of donating blood 
to the  biorepository will re -consent with the version that includes the blood donation to 
the BND  either at the next study visit, or if necessary, via an approved phone script.  
The ICF will describe that the HIPAA identifier , date of study visit, will be included o n all 
stored study data includ ing in the REDCap database on MRI images sent to the Central 
MRI Reading Site , and  on specimens within the BND. . The ICF also describes that 
 VA Central IRB Protocol Template – version 10/26/2012  Page 42 of 48 
 additional PHI including name, date of birth , social security number and medical record 
number may be sent to the Central MRI Reading Site if those elements are unable to be 
removed by the local sites prior to sending. Only study staff at each site, the Central MRI 
Reading Site study staff , the DCC,  and members of the DSMB  will have access to the 
study data that includes PHI. Once the study has concluded, study records will be 
maintained at each site for the duration of time required by each site regulations.   
8.0 Communication Plan  
8.1 Multi -site study  coordination p lan 
The Principal Study site will be responsible for initial submission and ongoing reporting 
to the VA Central IRB . The PI and PM will provide notification to st udy site Directors 
when VA Central IRB approval has been obtained . The Principa l Study site will provide 
support to both VA and non -VA study sites for obt aining local IRB approval.  The 
Principal Study site will be responsible for reconciling protocol -changing differences 
between IRBs . In addition, the Principal Study site  will provid e Standard Opera ting 
Procedures , a Manual of Operations & Procedures,  and data collection forms  to each 
site. An Investigator Meeting will familiarize the LSIs with the study prior to study start. 
As necessary, t he study monitor (PM)  will hold 1 training v isit with study staff at each 
site to review the protocol, study  documents, review data collection techniques, review 
communication plans , demonstrate and certify use of the REDCap database , inspect 
facilities and study materials, and verify site readiness  to participate in the study  prior to 
enrolment of subjects at the site.  Investigators are required to store all source 
documents  per study site requirements .  
8.2 Ongoing communication  
Local s ite investigators  will participate in regular LSI Research Tele conferences led by 
Dr. Spain and the PM to discuss  study -related matters  including but not limited to IRB 
issues, training, study preparation, subject  recruitment, data collection, REDCap 
database entry, adverse events, budget s, and publications. The PM wi th conduct  
regular (e.g.  monthly ) teleconferences with site study staff  for data collection and related  
issues. LSIs are expected to hold regular meetings with their site research staff  in order 
to review study progress, review adverse events, and other st udy matters . Email will 
also be utilized as a primary method of communicating information about changes to the 
protocol, informed consent, and HIPAA authorization. Communication about AEs, 
SAEs, unanticipated problems, or DSMB reports will also be conducte d by email, 
phone, or the LSI teleconferences as appropriate to the level of urgency of information 
 VA Central IRB Protocol Template – version 10/26/2012  Page 43 of 48 
 transmitted.  This information will be relayed  to the appropriate IRBs  under the direction 
of the DCC  according to the DSMP (sec. 6. 8). 
Initial and ongoing I RB approval documents will be provided by each study site  to the PI  
to ensure that no study activities occur without IRB approval.  Acknowledgment of these 
notifications will be maintained as documentation of understanding from each study site.  
Study sites will be notified when enrolment targets are reached, when sites have 
completed their final study visits, and when the entire study has completed. 
Acknowledgment of these notifications will be maintained as documentation of 
understanding from each study sit e. Study LSIs will have the opportunity to participate 
in manuscript preparation with authorship order related to recruitment achieved and/or 
level of participation in manuscript editing.  
8.3 Study monitoring  
Yearly on -site study monitoring visits and stud y closing  visits by the PM will be 
performed to assess critical study procedures including study data endpoints, subject 
safety, protocol compliance, and regulatory compliance. The monitoring may include the 
following: Audit data listings to source documen tation, ensure subject eligibility, verify 
reporting of adverse events, assess compliance with protocol, audit regulatory files, and 
ensure adequate site personnel training. The Central Research Pharmacy may request 
site pharmacy investigational drug accou ntability review during these visits. Centralized 
monitoring processes at the DCC occur at regular intervals and will include data quality 
checks, site performance checks, and safety reporting monitoring. Regular feedback 
and data queries will be issued to  each site by the DCC, and resolution of queries 
managed by the PM and DCC.  
 
 
 
 
 
 
 
 VA Central IRB Protocol Template – version 10/26/2012  Page 44 of 48 
 9.0 References  
1. Scalfari A, Neuhaus A, Daumer M, Muraro PA, Ebers GC. Onset of secondary 
progressive phase and long -term evolution of multiple sclerosis. J  Neurol 
Neurosurg Psychiatry. 2014;85(1):67 -75. 
2. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of 
an international survey. National Multiple Sclerosis Society (USA) Advisory 
Committee on Clinical Trials of New Agents  in Multiple Sclerosis. Neurology. 
1996;46(4):907 -11. 
3. Lo AC, Hadjimichael O, Vollmer TL. Treatment patterns of multiple sclerosis 
patients: a comparison of veterans and non -veterans using the NARCOMS 
registry. Mult Scler. 2005;11(1):33 -40. 
4. Minagar A,  Toledo EG, Alexander JS, Kelley RE. Pathogenesis of brain and spinal 
cord atrophy in multiple sclerosis. J Neuroimaging. 2004;14(3 Suppl):5S -10S.  
5. Bakshi R, Dandamudi VS, Neema M, De C, Bermel RA. Measurement of brain and 
spinal cord atrophy by magnetic  resonance imaging as a tool to monitor multiple 
sclerosis. J Neuroimaging. 2005;15(4 Suppl):30S -45S. 
6. Hickman SJ. Optic nerve imaging in multiple sclerosis. J Neuroimaging. 2007;17 
Suppl 1:42S -5S. 
7. Simon JH. Brain atrophy in multiple sclerosis: what w e know and would like to 
know. Mult Scler. 2006;12(6):679 -87. 
8. Smith AR, Shenvi SV, Widlansky M, Suh JH, Hagen TM. Lipoic acid as a potential 
therapy for chronic diseases associated with oxidative stress. Curr Med Chem. 
2004;11(9):1135 -46. 
9. Biewenga GP , Haenen GR, Bast A. The pharmacology of the antioxidant lipoic 
acid. Gen Pharmacol. 1997;29(3):315 -31. 
10. Biewenga GP, Dorstijn MA, Verhagen JV, Haenen GR, Bast A. Reduction of lipoic 
acid by lipoamide dehydrogenase. Biochem Pharmacol. 1996;51(3):233 -8. 
11. Schreibelt G, Musters RJ, Reijerkerk A, de Groot LR, van der Pol SM, Hendrikx 
EM, et al. Lipoic acid affects cellular migration into the central nervous system and 
stabilizes blood -brain barrier integrity. J Immunol. 2006;177(4):2630 -7. 
 VA Central IRB Protocol Template – version 10/26/2012  Page 45 of 48 
 12. Shay KP, Mi chels AJ, Li W, Kong AN, Hagen TM. Cap -independent Nrf2 
translation is part of a lipoic acid -stimulated detoxification stress response. Biochim 
Biophys Acta. 2012;1823(6):1102 -9. 
13. Jones RE, Moes N, Zwickey H, Cunningham CL, Gregory WL, Oken B. Treatment  
of experimental autoimmune encephalomyelitis with alpha lipoic acid and 
associative conditioning. Brain Behav Immun. 2008;22(4):538 -43. 
14. Morini M, Roccatagliata L, Dell'Eva R, Pedemonte E, Furlan R, Minghelli S, et al. 
Alpha -lipoic acid is effective in  prevention and treatment of experimental 
autoimmune encephalomyelitis. J Neuroimmunol. 2004;148(1 -2):146 -53. 
15. Yadav V, Marracci GH, Munar MY, Cherala G, Stuber LE, Alvarez L, et al. 
Pharmacokinetic study of lipoic acid in multiple sclerosis: comparing mice and 
human pharmacokinetic parameters. Mult Scler. 2010;16(4):387 -97. 
16. Reljanovic M, Reichel G, Rett K, Lobisch M, Schuette K, Moller W, et al. Trei.  
Varied clinical performance: MRI is an objective and quantitative outcome 
measures but can vary due  to acquisition techniques. Standardization of 
acquisition will include using the same MRI scanner at each site and uniform 
positioning for all participants. Participants will be permitted oral muscle relaxants 
or anxiolytics only during the MRI. Quality c ontrol processes (sec. D5) set in place 
by the MRI Central Processing Site will ensure ongoing quality at each site and 
across sites. Performance in clinical and patient -reported outcomes is known to 
fluctuate. Methods to address this are in D1f.ii)  trial  (ALADIN II). Alpha Lipoic Acid 
in Diabetic Neuropathy. Free Radic Res. 1999;31(3):171 -9. 
17. Yadav V, Marracci G, Lovera J, Woodward W, Bogardus K, Marquardt W, et al. 
Lipoic acid in multiple sclerosis: a pilot study. Mult Scler. 2005;11(2):159 -65. 
18. Spain R, Powers K, Murchison C, Heriza E, Winges K, Yadav V, et al. Lipoic acid 
in secondary progressive MS: A randomized controlled pilot trial. Neurol 
Neuroimmunol Neuroinflamm. 2017;4(5):e374.  
19. Marracci GH, Jones RE, McKeon GP, Bourdette DN. Alpha lipo ic acid inhibits T 
cell migration into the spinal cord and suppresses and treats experimental 
autoimmune encephalomyelitis. J Neuroimmunol. 2002;131(1 -2):104 -14. 
20. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al. 
Diagnostic criter ia for multiple sclerosis: 2010 revisions to the McDonald criteria. 
Ann Neurol. 2011;69(2):292 -302. 
 VA Central IRB Protocol Template – version 10/26/2012  Page 46 of 48 
 21. Fischer JS, Rudick RA, Cutter GR, Reingold SC. The Multiple Sclerosis Functional 
Composite Measure (MSFC): an integrated approach to MS clinical outcome  
assessment. National MS Society Clinical Outcomes Assessment Task Force. Mult 
Scler. 1999;5(4):244 -50. 
22. Cameron MH, Fitzpatrick M, Overs S, Murchison C, Manning J, Whitham R. 
Dalfampridine improves walking speed, walking endurance, and community 
partic ipation in veterans with multiple sclerosis: a longitudinal cohort study. Mult 
Scler. 2014;20(6):733 -8. 
23. Lamb SE, Jorstad -Stein EC, Hauer K, Becker C, Prevention of Falls Network E, 
Outcomes Consensus G. Development of a common outcome data set for fall  
injury prevention trials: the Prevention of Falls Network Europe consensus. J Am 
Geriatr Soc. 2005;53(9):1618 -22. 
24. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded 
disability status scale (EDSS). Neurology. 1983;33(11):1444 -52. 
25. Langdon DW, Amato MP, Boringa J, Brochet B, Foley F, Fredrikson S, et al. 
Recommendations for a Brief International Cognitive Assessment for Multiple 
Sclerosis (BICAMS). Mult Scler. 2012;18(6):891 -8. 
26. Drake AS, Weinstock -Guttman B, Morrow SA, Hoj nacki D, Munschauer FE, 
Benedict RH. Psychometrics and normative data for the Multiple Sclerosis 
Functional Composite: replacing the PASAT with the Symbol Digit Modalities Test. 
Mult Scler. 2010;16(2):228 -37. 
27. Woods SP, Delis DC, Scott JC, Kramer JH, Ho ldnack JA. The California Verbal 
Learning Test --second edition: test -retest reliability, practice effects, and reliable 
change indices for the standard and alternate forms. Arch Clin Neuropsychol. 
2006;21(5):413 -20. 
28. Benedict RHB, Benedict RHB, Psycholo gical Assessment Resources Inc. Hopkins 
verbal learning test --revised / brief visuospacial memory test --revised. Professional 
manual supplement. Lutz, Flor.: Psychological Assessment Resources; 1997. iv, 
57 pages p.  
29. Cella D, Riley W, Stone A, Rothrock N, Reeve B, Yount S, et al. The Patient -
Reported Outcomes Measurement Information System (PROMIS) developed and 
tested its first wave of adult self -reported health outcome item banks: 2005 -2008. J 
Clin Epidemiol. 2010;63(11):1179 -94. 
 VA Central IRB Protocol Template – version 10/26/2012  Page 47 of 48 
 30. Kroenke K, Spitzer  RL, Williams JB. The PHQ -9: validity of a brief depression 
severity measure. J Gen Intern Med. 2001;16(9):606 -13. 
31. Noonan VK, Cook KF, Bamer AM, Choi SW, Kim J, Amtmann D. Measuring fatigue 
in persons with multiple sclerosis: creating a crosswalk betwe en the Modified 
Fatigue Impact Scale and the PROMIS Fatigue Short Form. Qual Life Res. 
2012;21(7):1123 -33. 
32. Smith SM, Jenkinson M, Woolrich MW, Beckmann CF, Behrens TE, Johansen -
Berg H, et al. Advances in function al and structural MR image analysis and 
implementation as FSL. Neuroimage. 2004;23 Suppl 1:S208 -19. 
33. Altmann DR, Jasperse B, Barkhof F, Beckmann K, Filippi M, Kappos LD, et al. 
Sample sizes for brain atrophy outcomes in trials for secondary progressive 
multiple sclerosis. Neurology. 2009;72(7):595 -601. 
 
 VA Central IRB Protocol Template – version 10/26/2012  Page 48 of 48 
 Appendix  – Supporting Documents List       
A.   Letter of Support, Pure E ncaps  
B. Recruitment Flyer  
C. Recruitment Letter to MS Practitioners  
D. Recruitment Telephone Script  
E. Recruitment Email Blast  
F. Timed 25 Foot Walk & 9 Hole Peg Test  
G. Expanded Disability Status Scale  
H. Symbol Digit Modalities Test  
I. California Verbal Learning Test - 2nd edition  
J. Brief Visuospatial Memory Test – Revised  
K. PROMIS - Pain Intensity  
L. PROMIS - Pain Interference  
M. PROMIS - Ability Partic in Soc Roles and Activities  
N. Patient Health Questionnaire -9 
O. Sleep Scale from the Medical Outcomes Study   
P. Modified Fatigue Impact Scale  
Q. Fall Count Diary  
R. Suicide Behaviors Questionnaire -Revised  
S. Subject Blinding Ques tionnaire  
T. Fall s Efficacy Scale -International  
U. Study Drug Instructions  
V. Godin Leisure -Time Exercise Questionnaire , modified  
W. ResearchMatch Message  
X. Short URL  
Y. LAP MS sticker  
Z. LAPMS Facebook page  
AA. LAPMS Facebook ad  
BB. LAPMS webpage  
CC. LAPM S Webpage Content  
 
 
 
 
 
 
 
 